Travers Smith LLP has advised an investment vehicle backed by long-standing client 3i Group on its acquisition of bioprocessing solutions company Cellon.
Cellon is a manufacturer of single-use products for bioprocessing, storage, and transport of sterile solutions for pharmaceutical and biotech companies in the production of biological drugs, vaccines and therapies. Its products include sterile bottles for the production of biologic drugs, custom tube and bottle sets and platinum-cured silicone tubing.
3i Group has used its acquisition of Cellon, together with Silicone Altimex and TBL Performance Plastics, to establish a platform serving the single use bioprocessing market.
Richard Relyea, Partner and Managing Director at 3i Group, said of the transaction: “In combining Cellon, TBL and Silicone Altimex we are establishing a platform with a strong product suite of leading SUT solutions and clean room production capacity in North America and Europe. We will continue to invest in the innovation, production capacity and geographic footprint of this high growth market to better serve our customers.”
The Travers Smith team was led by Private Equity & Financial Sponsors Partner Lucie Cawood, with support from Private Equity & Financial Sponsors Associates Raphaella Gabrasadig and Eric Van Winssen. Tax advice was provided by Partner Madeline Gowlett and Associate Aimee Hutchinson.
Arendt & Medernach (led by Alexander Olliges) acted as Luxembourg advisers to 3i Group. Kirkland & Ellis (co-led by Sam Whittaker, Stuart Boyd and Michael Sartor) also provided advice to 3i.
Allen & Overy (led by Jacques Graas) advised the sellers.